Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial.
Hisamatsu T, Kunisaki R, Nakamura S, Tsujikawa T, Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M; CERISIER Trial group. Hisamatsu T, et al. Among authors: yokoyama t, yokoyama k. Intest Res. 2018 Jul;16(3):494-498. doi: 10.5217/ir.2018.16.3.494. Epub 2018 Jul 27. Intest Res. 2018. PMID: 30090050 Free PMC article. No abstract available.
The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management.
Hibi T, Panaccione R, Katafuchi M, Yokoyama K, Watanabe K, Matsui T, Matsumoto T, Travis S, Suzuki Y. Hibi T, et al. Among authors: yokoyama k. J Crohns Colitis. 2017 Oct 27;11(11):1302-1308. doi: 10.1093/ecco-jcc/jjx085. J Crohns Colitis. 2017. PMID: 28981622 Free PMC article.
Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in Japan.
Fukushima K, Sugita A, Futami K, Takahashi KI, Motoya S, Kimura H, Yoshikawa S, Kinouchi Y, Iijima H, Endo K, Hibi T, Watanabe M, Sasaki I, Suzuki Y; Surgical Research Group, the Research Committee of Inflammatory Bowel Disease, the Ministry of Health, Welfare and Labor of Japan. Fukushima K, et al. Surg Today. 2018 Jun;48(6):584-590. doi: 10.1007/s00595-018-1627-x. Epub 2018 Jan 30. Surg Today. 2018. PMID: 29383596 Clinical Trial.
Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.
Kobayashi T, Hisamatsu T, Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto T, Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa T, Sasaki M, Yokoyama K, Yoshimura N, Watanabe K, Katafuchi M, Watanabe M, Hibi T. Kobayashi T, et al. Among authors: yokoyama k. Intest Res. 2018 Apr;16(2):168-177. doi: 10.5217/ir.2018.16.2.168. Epub 2018 Apr 30. Intest Res. 2018. PMID: 29743830 Free PMC article. Review.
Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial.
Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, Yamamoto T, Hanai H, Omori T, Kanai T, Hibi T; CAPTAIN study Group. Naganuma M, et al. Among authors: yokoyama y. J Gastroenterol. 2020 Apr;55(4):390-400. doi: 10.1007/s00535-019-01651-0. Epub 2019 Dec 6. J Gastroenterol. 2020. PMID: 31811562 Clinical Trial.
Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes.
Watanabe C, Nagahori M, Fujii T, Yokoyama K, Yoshimura N, Kobayashi T, Yamagami H, Kitamura K, Takashi K, Nakamura S, Naganuma M, Ishihara S, Esaki M, Yonezawa M, Kunisaki R, Sakuraba A, Kuji N, Miura S, Hibi T, Suzuki Y, Hokari R. Watanabe C, et al. Among authors: yokoyama k. Dig Dis Sci. 2021 Feb;66(2):577-586. doi: 10.1007/s10620-020-06221-6. Epub 2020 Apr 6. Dig Dis Sci. 2021. PMID: 32249373
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T; AJM300 Study Group. Matsuoka K, et al. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):648-657. doi: 10.1016/S2468-1253(22)00022-X. Epub 2022 Mar 30. Lancet Gastroenterol Hepatol. 2022. PMID: 35366419 Clinical Trial.
3,313 results